Overview

Preterm Birth Prevention and Management Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

The rising necessity of preventing preterm births and increased emphasis on targeted therapies and care standards are some of the key factors contributing to the market growth. According to the data provided by the WHO, every year, over 15 million births are preterm. Complications arising from preterm births is the primary cause of mortality in children under the age of 5 with over 1 million deaths recorded in 2015. Over 70% of these deaths are preventable with cost-effective interventions. Due to these factors, it is estimated that the market shall propel during the forecast period.    
Treating progesterone during the pregnancy process shall help many women to be prevented from premature birth and a 17P shot is very effective in such cases. Vaginal progesterone and progesterone shots are two types of progesterone treatments. Vaginal progesterone helps in reducing premature birth in case the women is carrying one baby and has a shorter cervix. The progesterone shots help in reducing the risk of premature birth if the women previously had a premature birth. Such factors shall boost the preterm birth prevention and management market growth.

Market Segmentation:

By Therapy Type
•    Progesterone Therapy
•    Corticosteroid Therapy
•    Tocolytics Therapy
•    Antibiotics Therapy 
•    Heparin Profylaxis Therapy
•    Others    
By Route of Administration
•    Oral 
•    Parenteral
•    Vaginal
By Distribution Channel
•    Drug Stores
•    Hospital Pharmacies
•    Mail Order Pharmacies
•    E-Pharmacies
•    Retail Pharmacies
•    Others      
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is fragmented into therapy type, route of administration, distribution channel and region. The therapy type segment is categorised into progesterone therapy, tocolytics therapy, corticosteroid therapy, antibiotics therapy, heparin profylaxis therapy and others. The route of administration segment is diversified into oral, vaginal and parenteral. The oral route is predicted to hold the largest preterm birth prevention and management market share during the forecast period. The distribution channel segment is bifurcated into hospital pharmacies, online pharmacies, drug stores. 

Regional Analysis:

The North America region is predicted to lead the market during the forecast period owing to increased birth rates, rising awareness amongst women regarding preterm birth and major market players have their headquarters in the region. As per the Centers for Disease Control and Prevention, over 1 in every 10 infants were born premature in the US in the year 2018. Such statistics shall provide a boost to the market growth in the region.

Competitive Landscape:                              

The key players associated are AbbVie Inc., Allergan, AMAG Pharmaceuticals, Bayer AG, Ferring B.V., Merck & Co. Inc., Mylan N.V., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global the preterm birth prevention and management market by therapy type, by route of administration, by distribution channel and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions 

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
        1.1 Objectives of the Study 
        1.2 Market Definition 
        1.3 Market Scope 
                1.3.1 Years Considered for the Study
                1.3.2 Market Covered
        1.4 Currency
        1.5 Limitations 
        1.6 Stakeholders     
2. Research Methodology 
         2.1 Research Data 
              2.1.1 Secondary Data
                       2.1.1.1 Key Data from Secondary Sources
              2.1.2 Primary Data
                       2.1.2.1 Key Data from Primary Sources
         2.2 Market Size Estimation 
         2.3 Market Breakdown and Data Triangulation 
         2.4 Assumptions for the Study  
3. Executive Summary
         3.1 Market Outlook
         3.2 Segment Outlook
         3.3 Competitive Insights
4. Market Variables, Trends & Scope
         4.1 Market Lineage Outlook
         4.2 Penetration and Growth Prospect Mapping
         4.3 Industry Value Chain Analysis
         4.4 Cost Analysis Breakdown
         4.5 Technology Overview
         4.6 Regulatory Framework on Country Level
               4.6.1 Reimbursement Framework    
               4.6.2 Standards and Compliances
5. Market Overview
         5.1 Market Dynamics
              5.1.1 Market Driver Analysis         
              5.1.2 Market Restraint Analysis         
              5.1.3 Industry Challenges                   
6. Market Analysis tools                      
         6.1 Industry Analysis - Porter’s
                     6.1.1 Supplier Power
                     6.1.2 Buyer Power
                     6.1.3 Substitution Threat
                     6.1.4 Threat from new entrants
                     6.1.5 Competitive Rivalry                  
         6.2 Pestel Analysis
                     6.2.1 Political Landscape
                     6.2.2 Environmental Landscape
                     6.2.3 Social landscape
                     6.2.4 Technology landscape
                     6.2.5 Legal Landscape
7. Preterm Birth Prevention and Management Market, By Therapy Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
         7.1 Progesterone Therapy
         7.2 Corticosteroid Therapy
         7.3 Tocolytics Therapy
         7.4 Antibiotics Therapy 
         7.5 Heparin Profylaxis Therapy
         7.6 Others                        
8. Preterm Birth Prevention and Management Market, By Route of Administration Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
         8.1 Oral 
         8.2 Parenteral
         8.3 Vaginal        
9. Preterm Birth Prevention and Management Market, By Distribution Channel Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
         9.1 Drug Stores
         9.2 Hospital Pharmacies
         9.3 Mail Order Pharmacies
         9.4 E-Pharmacies
         9.5 Retail Pharmacies
         9.6 Others           
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         10.1. Introduction
         10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                10.2.1. U.S.
                10.2.2. Canada
                10.2.3. Mexico 
                10.2.4. Rest of North America
         10.3 Market Size (USD Mn) Forecast for North America 2020-2027
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         11.1. Introduction
         11.2. Regional Market Trends
         11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                11.3.1. Brazil
                11.3.2. Venezuela
                11.3.3. Argentina
                11.3.4. Rest of Latin America
         11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         12.1. Introduction
         12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
               12.2.1. Germany
                12.2.2. U.K
                12.2.3. France
                12.2.4. Italy
                12.2.5 Switzerland
                12.2.6. Spain
                12.2.7. Russia
                12.2.8. Poland
                12.2.9. Rest of Western Europe
         12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
            13.1 Introduction
            13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                 13.2.1 Japan
                 13.2.2 China
                 13.2.3 Singapore
                 13.2.4 Korea         
                 13.2.5 India
                 13.2.6 Australia and New Zealand
                 13.2.7 ASEAN
                 13.2.8 Rest of Asia Pacific
            13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1 Introduction
    14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
        14.2.1 UAE
        14.2.2 South Africa
        14.2.3 Egypt
        14.2.4 Saudi Arabia
        14.2.5 Rest of MEA
    14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    15.1 AbbVie Inc.
              15.1.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.1.2. Product Portfolio
              15.1.3. SWOT Analysis
              15.1.4. Financial Overview
              15.1.5. Strategic Overview
    15.2 Allergan
              15.2.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.2.2. Product Portfolio
              15.2.3. SWOT Analysis
              15.2.4. Financial Overview
              15.2.5. Strategic Overview
    15.3 AMAG Pharmaceuticals
              15.3.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.3.2. Product Portfolio
              15.3.3. SWOT Analysis
              15.3.4. Financial Overview
              15.3.5. Strategic Overview
    15.4 Bayer AG
              15.4.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.4.2. Product Portfolio
              15.4.3. SWOT Analysis
              15.4.4. Financial Overview
              15.4.5. Strategic Overview
    15.5 Ferring B.V.
              15.5.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.5.2. Product Portfolio
              15.5.3. SWOT Analysis
              15.5.4. Financial Overview
              15.5.5. Strategic Overview
    15.6 Merck & Co. Inc.
              15.6.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.6.2. Product Portfolio
              15.6.3. SWOT Analysis
              15.6.4. Financial Overview
              15.6.5. Strategic Overview
    15.7 Pfizer Inc.
              15.7.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.7.2. Product Portfolio
              15.7.3. SWOT Analysis
              15.7.4. Financial Overview
              15.7.5. Strategic Overview
    15.8 Mylan N.V.
              15.8.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.8.2. Product Portfolio
              15.8.3. SWOT Analysis
              15.8.4. Financial Overview
              15.8.5. Strategic Overview    
    15.9 Teva Pharmaceutical Industries Ltd.
              15.9.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.9.2. Product Portfolio
              15.9.3. SWOT Analysis
              15.9.4. Financial Overview
              15.9.5. Strategic Overview
16. Impact of COVID-19
      16.1. Positive influence on the healthcare industry
      16.2. The financial disruption of the manufacturing sector
      16.3. Impact of COVID-19 on emerging companies
      16.4. Significant mandates in the healthcare regulations initiated by administrations
      16.5. The overall economic slowdown of the developing and developed nations
17. Competitive Intelligence and Competitive Matrix
      17.1 Competitive Intelligence
      17.2 Competitive Matrix
18. Major Deals and Strategic Alliances Analysis
      18.1 Joint ventures
      18.2 Mergers and acquisitions              
      18.3 Licensing and partnerships
      18.4 Technology Collaborations
      18.5 Strategic Divestments
      18.6 Market Entry Strategies                        
19. Relevant Case Studies and Latest News Updates
20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics 

Tables

Figures